Believe me… negotiations for partnership on Nash is the golden egg we all have been waiting for. Don’t be confused with predictions as facts. Go back and listen to the grammar of how things were said. You will not find an omission that boldly states that we are in negotiations for Nash. You will find statement like… with 2 BTD’s there is no company that has not been bought out… by Dr. Scott Kelly. Other statements that say… When we release the analysis of the 700mg trial we will send it to 1000 pharmas across the world and we will partner with someone for Nash… by Nader. These statements were forward looking and they can make statements like these.
The bottom line is we know nothing of why Nader was fired with a golden parachute. This is/was a negotiated firing. We know nothing about any future Nash results or if they were courting a Pharma for negotiations on a partnership or buyout. We tend to speculate but reality is it could be as simple as the new direction for the company is no more PR’s unless it is a material event. The PR’s have hammered us and the stock price shows this. Nader was not able to move the stock price on future timelines and predictions any longer. His usefulness was over. Hence a quite period until a new CEO and direction for the company could be everything we are waiting for.
I believe in butterfly’s and rainbows giving us the best chance at success. I hope that we are in negotiations for a partnership. I explicitly do not want a buyout. There is no money in a buyout compared to a partnership on just one licensing of either Nash or mTNBC. We can partner on either in my opinion. Don’t take away the golden egg that is a platform drug in Leronlimab that is what we have all been invested in for some measly buyout offer. That won’t meet our expectations in the least bit. A platform drug is what we have… this is very much the golden opportunity and there is huge returns to be had if we can just get the first approval to finance all the other trials and future approvals. Don’t give away the farm at this point in a buyout. It would be a disservice to all the longs to sell out now at the bottom for some measly $5-$10 a share offer. Nader was right and an engineer can do math. We will easily hit 3 digits in a year or two after our first approval. We are the little engine that could… don’t discount the science and the math of market values for the block buster indications we are showing in our trials. They are huge markets. Ones that could very well make us all rich. Let’s hope that we can partner for one indication and become our own pharmaceutical company for the rest. Let’s get a CEO that has made this transition from biotech to pharmaceutical and let him grow our company. That’s what I am looking for. What are you looking for?
The bottom line is we know nothing of why Nader was fired with a golden parachute. This is/was a negotiated firing. We know nothing about any future Nash results or if they were courting a Pharma for negotiations on a partnership or buyout. We tend to speculate but reality is it could be as simple as the new direction for the company is no more PR’s unless it is a material event. The PR’s have hammered us and the stock price shows this. Nader was not able to move the stock price on future timelines and predictions any longer. His usefulness was over. Hence a quite period until a new CEO and direction for the company could be everything we are waiting for.
I believe in butterfly’s and rainbows giving us the best chance at success. I hope that we are in negotiations for a partnership. I explicitly do not want a buyout. There is no money in a buyout compared to a partnership on just one licensing of either Nash or mTNBC. We can partner on either in my opinion. Don’t take away the golden egg that is a platform drug in Leronlimab that is what we have all been invested in for some measly buyout offer. That won’t meet our expectations in the least bit. A platform drug is what we have… this is very much the golden opportunity and there is huge returns to be had if we can just get the first approval to finance all the other trials and future approvals. Don’t give away the farm at this point in a buyout. It would be a disservice to all the longs to sell out now at the bottom for some measly $5-$10 a share offer. Nader was right and an engineer can do math. We will easily hit 3 digits in a year or two after our first approval. We are the little engine that could… don’t discount the science and the math of market values for the block buster indications we are showing in our trials. They are huge markets. Ones that could very well make us all rich. Let’s hope that we can partner for one indication and become our own pharmaceutical company for the rest. Let’s get a CEO that has made this transition from biotech to pharmaceutical and let him grow our company. That’s what I am looking for. What are you looking for?
21
